Pioneering a Multi-Antigen Approach
Harnessing millions of years of immunologic evolution, Marker’s Multi-Antigen Recognizing (MAR) T cell therapy is designed to recognize and kill highly heterogeneous tumors without the need for genetic modifications. The MAR-T cell technology provides patients with natural T cells capable of recognizing and killing tumor cells effectively.
Our MAR-T cell technology was developed at Baylor College of Medicine and was tested across seven different clinical indications showing an excellent safety profile and durable anti-tumor responses in both hematologic malignancies and solid tumors.
Marker’s lead product candidate, MT-601, recognizes six tumor-specific antigens (Survivin, PRAME, NY-ESO-1, MAGE-A4, SSX2, WT-1) and is currently evaluated in a Phase 1 study in patients with lymphoma who relapsed or are ineligible to receive anti-CD19 CAR-T cell therapy.